Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2

Status

Completed 9Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × tipifarnib × Clear all
NCT00361088 2013-11-25

A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Terminated
42 enrolled
Plasma cell

Multiple Myeloma

NCT00243035 2013-10-08

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
64 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡